SCHEMBL2293740

SCHEMBL2293740

COC(=O)C(NC(=O)c1csc(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)n1)C(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.58
IDE P14735 1/20 0.58
MAPK10 P53779 1/20 0.58
DGAT1 O75907 1/20 0.57
CSGALNACT1 Q8TDX6 2/20 0.55
MAPT P10636 7/20 0.54
KDM4E B2RXH2 3/20 0.54
NR1H4 Q96RI1 1/20 0.51
POLB P06746 2/20 0.51
LMNA P02545 2/20 0.48
ALDH1A1 P00352 1/20 0.48
KDR P35968 2/20 0.47
PDGFRB P09619 1/20 0.47
PLK4 O00444 1/20 0.45
AURKA O14965 1/20 0.45
MAPK13 O15264 1/20 0.45
JAK2 O60674 1/20 0.45
MAP4K4 O95819 1/20 0.45
ABL1 P00519 1/20 0.45
LCK P06239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293738 1.00 MAPK1 (0.58) MAPK1IDEMAPK10DGAT1CSGALNACT1
SCHEMBL2296476 0.91 DGAT1 (0.68) MAPK1IDEMAPK10DGAT1CSGALNACT1
SCHEMBL2296474 0.91 DGAT1 (0.68) MAPK1IDEMAPK10DGAT1CSGALNACT1
SCHEMBL2301345 0.85 CSGALNACT1 (0.52) MAPK1CSGALNACT1MAPTKDM4EPOLB
SCHEMBL2301342 0.85 CSGALNACT1 (0.52) MAPK1CSGALNACT1MAPTKDM4EPOLB
SCHEMBL2301344 0.84 DGAT1 (0.52) DGAT1CSGALNACT1MAPTPOLBLMNA
SCHEMBL2301334 0.84 DGAT1 (0.52) DGAT1CSGALNACT1MAPTPOLBLMNA
SCHEMBL1756239 0.82 DGAT1 (0.83) DGAT1CSGALNACT1MAPTLMNAKDR
SCHEMBL2300971 0.81 NPC1 (0.47) POLBNPC1MEN1KMT2ASMN1; SMN2
SCHEMBL2300968 0.81 NPC1 (0.47) POLBNPC1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT MAPK1 1777/4885IDE 472/4885MAPK10 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.